AIP gene and familial isolated pituitary adenomas

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 71-79

  Ozfirat, Zehra ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aryl hydrocarbon receptor (AhR); Aryl hydrocarbon receptor interacting protein (AIP); Familial isolated pituitary adenoma (FIPA); Tumorigenesis

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ARYL HYROCARBON RECEPTOR INTERACTING PROTEIN; CORTICOTROPIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLIC AMP; DIOXIN; DNA; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3; GLUCOCORTICOID RECEPTOR; GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA13; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHODIESTERASE; PROLACTIN; PROTEIN RET; RECEPTOR PROTEIN; SURVIVIN; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; TRANSLOCASE OF THE OUTER MEMBRANE OF MITOCHONDRIA 20; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADRENAL FUNCTION; ARTICLE; CARNEY COMPLEX; CELL CYCLE ARREST; CPG ISLAND; DNA METHYLATION; ENDOCRINE FUNCTION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOSITY LOSS; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REPRODUCTION; THYROID FUNCTION;

ADENOMA; ANIMALS; CYCLIC AMP; DIOXINS; GTP-BINDING PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORIC DIESTER HYDROLASES; PITUITARY GLAND; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RET; RATS;

EID: 77955326627     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.05.001     Document Type: Article

References (97)

1. Baccarelli A., Giacomini S.M., Corbetta C., Landi M.T., Bonzini M., Consonni D., Grillo P., Patterson D.G., Pesatori A.C., Bertazzi P.A. Neonatal thyroid function in Seveso 25 years after maternal exposure to dioxin. PLoS Med. 2008, 5:e161.
2. Barhoover M.A., Hall J.M., Greenlee W.F., Thomas R.S. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol. Pharmacol. 2010, 77(2):195-201.
3. Barlier A., Vanbellinghen J.F., Daly A.F., Silvy M., Jaffrain-Rea M.L., Trouillas J., Tamagno G., Cazabat L., Bours V., Brue T., Enjalbert A., Beckers A. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2007, 92:1952-1955.
4. INK4c) gene mutations in a large cohort of pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic features. Proceedings of the 90th Annual Meet of the Endocrine Society OR38-1 2008.
5. Benlian P., Giraud S., Lahlou N., Roger M., Blin C., Holler C., Lenoir G., Sallandre J., Calender A., Turpin G. Familial acromegaly: a specific clinical entity-further evidence from the genetic study of a three-generation family. Eur. J. Endocrinol. 1995, 133:451-456.
6. Bestervelt L.L., Pitt J.A., Nolan C.J., Piper W.N. TCDD alters pituitary-adrenal function. II. Evidence for decreased bioactivity of ACTH. Neurotoxicol. Teratol. 1993, 15:371-376.
7. Bestervelt L.L., Pitt J.A., Piper W.N. Evidence for Ah receptor mediation of increased ACTH concentrations in primary cultures of rat anterior pituitary cells exposed to TCDD. Toxicol. Sci. 1998, 46:294-299.
8. Boikos S.A., Horvath A., Heyerdahl S., Stein E., Robinson-White A., Bossis I., Bertherat J., Carney J.A., Stratakis C.A. Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions. Horm. Metab. Res. 2008, 40:347-353.
9. Bolger G.B., Peden A.H., Steele M.R., MacKenzie C., McEwan D.G., Wallace D.A., Huston E., Baillie G.S., Houslay M.D. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 2003, 278:33351-33363.
10. Canibano C., Rodriguez N.L., Saez C., Tovar S., Garcia-Lavandeira M., Borrello M.G., Vidal A., Costantini F., Japon M., Dieguez C., Alvarez C.V. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 2007, 26:2015-2028.
11. Cao Y., Winneke G., Wilhelm M., Wittsiepe J., Lemm F., Furst P., Ranft U., Imohl M., Kraft M., Oesch-Bartlomowicz B., Kramer U. Environmental exposure to dioxins and polychlorinated biphenyls reduce levels of gonadal hormones in newborns: results from the Duisburg cohort study. Int. J. Hyg. Environ. Health 2008, 211:30-39.
12. Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem. 1997, 272:11452-11456.
13. Carver L.A., LaPres J.J., Jain S., Dunham E.E., Bradfield C.A. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem. 1998, 273:33580-33587.
14. Cazabat L., Libe R., Perlemoine K., Rene-Corail F., Burnichon N., Gimenez-Roqueplo A.P., Dupasquier-Fediaevsky L., Bertagna X., Clauser E., Chanson P., Bertherat J., Raffin-Sanson M.L. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 2007, 157:1-8.
15. Cazabat L., Guillaud-Bataille M., Bertherat J., Raffin-Sanson M.L. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm. Res. 2009, 71:132-141.
16. Chahal, H.S., Chapple, J.P., Frohman, L.A., Grossman, A.B., Korbonits, M., 2010. Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas. Trends Endocrinol. Metab. (in press).
17. Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., Valdes-Socin H., Rohmer V., Tamburrano G., Borson-Chazot C., Estour B., Ciccarelli E., Brue T., Ferolla P., Emy P., Colao A., De Menis E., Lecomte P., Penfornis F., Delemer B., Bertherat J., Wemeau J.L., de Herder W.W., Archambeaud F., Stevenaert A., Calender A., Murat A., Cavagnini F., Beckers A. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab. 2006, 91:3316-3323.
18. Daly A.F., Vanbellinghen J.F., Khoo S.K., Jaffrain-Rea M.L., Naves L.A., Guitelman M.A., Murat A., Emy P., Gimenez-Roqueplo A.P., Tamburrano G., Raverot G., Barlier A., De Herder W., Penfornis A., Ciccarelli E., Estour B., Lecomte P., Gatta B., Chabre O., Sabate M.I., Bertagna X., Garcia B.N., Stalldecker G., Colao A., Ferolla P., Wemeau J.L., Caron P., Sadoul J.L., Oneto A., Archambeaud F., Calender A., Sinilnikova O., Montanana C.F., Cavagnini F., Hana V., Solano A., Delettieres D., Luccio-Camelo D.C., Basso A., Rohmer V., Brue T., Bours V., Teh B.T., Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 2007, 92:1891-1896.
19. de Oliveira S.K., Smolenski A. Phosphodiesterases link the aryl hydrocarbon receptor complex to cyclic nucleotide signaling. Biochem. Pharmacol. 2009, 77:723-733.
20. de Oliveira S.K., Hoffmeister M., Gambaryan S., Muller-Esterl W., Guimaraes J.A., Smolenski A.P. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem. 2007, 282:13656-13663.
21. Egeland G.M., Sweeney M.H., Fingerhut M.A., Wille K.K., Schnorr T.M., Halperin W.E. Total serum testosterone and gonadotropins in workers exposed to dioxin. Am. J. Epidemiol. 1994, 139:272-281.
22. Froidevaux M.S., Berg P., Seugnet I., Decherf S., Becker N., Sachs L.M., Bilesimo P., Nygard M., Pongratz I., Demeneix B.A. The co-chaperone XAP2 is required for activation of hypothalamic thyrotropin-releasing hormone transcription in vivo. EMBO Rep. 2006, 7:1035-1039.
23. Gadelha M.R., Prezant T.R., Une K.N., Glick R.P., Moskal S.F., Vaisman M., Melmed S., Kineman R.D., Frohman L.A. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J. Clin. Endocrinol. Metab. 1999, 84:249-256.
24. Gadelha M.R., Une K.N., Rohde K., Vaisman M., Kineman R.D., Frohman L.A. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J. Clin. Endocrinol. Metab. 2000, 85:707-714.
25. Georgitsi M., Raitila A., Karhu A., Tuppurainen K., Makinen M.J., Vierimaa O., Paschke R., Saeger W., van der Luijt R.B., Sane T., Robledo M., De M.E., Weil R.J., Wasik A., Zielinski G., Lucewicz O., Lubinski J., Launonen V., Vahteristo P., Aaltonen L.A. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl. Acad. Sci. USA 2007, 104:4101-4105.
26. Georgitsi M., Heliovaara E., Paschke R., Kumar A.V., Tischkowitz M., Vierimaa O., Salmela P., Sane T., De M.E., Cannavo S., Gundogdu S., Lucassen A., Izatt L., Aylwin S., Bano G., Hodgson S., Koch C.A., Karhu A., Aaltonen L.A. Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 2008, 93:4146-4151.
27. Hahn M.E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact. 2002, 141:131-160.
28. Halpin D.M. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3:543-561.
29. Heliovaara E., Raitila A., Launonen V., Paetau A., Arola J., Lehtonen H., Sane T., Weil R.J., Vierimaa O., Salmela P., Tuppurainen K., Makinen M., Aaltonen L.A., Karhu A. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am. J. Pathol. 2009, 175:2501-2507.
30. Horvath A., Stratakis C.A. Clinical and molecular genetics of acromegaly: MEN1, Carney complex. McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev. Endocr. Metab Disord. 2008, 9:1-11.
31. Horvath A., Stratakis C.A. Unraveling the molecular basis of micronodular adrenal hyperplasia. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15:227-233.
32. Horvath A., Boikos S., Giatzakis C., Robinson-White A., Groussin L., Griffin K.J., Stein E., Levine E., Delimpasi G., Hsiao H.P., Keil M., Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S., Cramer K., Gaillard R.C., Bertagna X., Carney J.A., Bertherat J., Bossis I., Stratakis C.A. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Gen. 2006, 38:794-800.
33. Horvath A., Giatzakis C., Tsang K., Greene E., Osorio P., Boikos S., Libe R., Patronas Y., Robinson-White A., Remmers E., Bertherat J., Nesterova M., Stratakis C.A. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur. J. Hum. Genet. 2008, 16:1245-1253.
34. Horvath A., Mericq V., Stratakis C.A. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N. Engl. J. Med. 2008, 358:750-752.
35. Huang G., Elferink C.J. Multiple mechanisms are involved in Ah receptor-mediated cell cycle arrest. Mol. Pharmacol. 2005, 67:88-96.
36. Igreja, S.C., Chahal, H.S., King, P.J., Bolger, G.B., Srirangalingam, U., Guasti, L., Chapple, J.P., Trivellin, G., Gueorguiev, M., Guegan, K., Stals, K., Khoo, B., Kumar, A.V., Ellard, S., Grossman, A.B., Korbonits, M., 2010. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mutat. (in press).
37. Iwata T., Yamada S., Mizusawa N., Golam H.M., Sano T., Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxf.) 2007, 66:499-502.
38. Jaffrain-Rea M.L., Angelini M., Gargano D., Tichomirowa M.A., Daly A.F., Vanbellinghen J.F., D'Innocenzo E., Barlier A., Giangaspero F., Esposito V., Ventura L., Arcella A., Theodoropoulou M., Naves L.A., Fajardo C., Zacharieva S., Rohmer V., Brue T., Gulino A., Cantore G., Alesse E., Beckers A. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 2009, 16:1029-1043.
39. Jennings J., Georgitsi M., Holdaway I., Daly A., Tichomirowa M., Beckers A., Aaltonen L., Karhu A., Cameron F. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. Eur. J. Endocrinol. 2009, 161:799-804.
40. Jorge B.H., Agarwal S.K., Lando V.S., Salvatori R., Barbero R.R., Abelin N., Levine M.A., Marx S.J., Toledo S.P. Study of the multiple endocrine neoplasia type 1, growth hormone-releasing hormone receptor, Gs alpha, and Gi2 alpha genes in isolated familial acromegaly. J. Clin. Endocrinol. Metab. 2001, 86:542-544.
41. Jung K.K., Kim S.Y., Kim T.G., Kang J.H., Kang S.Y., Cho J.Y., Kim S.H. Differential regulation of thyroid hormone receptor-mediated function by endocrine disruptors. Arch. Pharm. Res. 2007, 30:616-623.
42. Kang B.H., Altieri D.C. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Biol. Chem. 2006, 281:24721-24727.
43. Kashuba E.V., Gradin K., Isaguliants M., Szekely L., Poellinger L., Klein G., Kazlauskas A. Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein. J. Biol. Chem. 2006, 281:1215-1223.
44. Kazlauskas A., Poellinger L., Pongratz I. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J. Biol. Chem. 1999, 274:13519-13524.
45. Kazlauskas A., Poellinger L., Pongratz I. The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor. J. Biol. Chem. 2000, 275:41317-41324.
46. Kazlauskas A., Poellinger L., Pongratz I. Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90. J. Biol. Chem. 2002, 277:11795-11801.
47. Khoo S.K., Pendek R., Nickolov R., Luccio-Camelo D.C., Newton T.L., Massie A., Petillo D., Menon J., Cameron D., Teh B.T., Chan S.P. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. Endocr. Relat. Cancer 2009, 16:157-163.
48. Kolluri S.K., Weiss C., Koff A., Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev. 1999, 13:1742-1753.
49. Kolluri S.K., Balduf C., Hofmann M., Gottlicher M. Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res. 2001, 61:8534-8539.
50. Krawczak M., Ball E.V., Cooper D.N. Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. Am. J. Hum. Genet. 1998, 63:474-488.
51. Laenger A., Lang-Rollin I., Kozany C., Zschocke J., Zimmermann N., Ruegg J., Holsboer F., Hausch F., Rein T. XAP2 inhibits glucocorticoid receptor activity in mammalian cells. FEBS Lett. 2009, 583:1493-1498.
52. Leontiou C.A., Gueorguiev M., van der S.J., Quinton R., Lolli F., Hassan S., Chahal H.S., Igreja S.C., Jordan S., Rowe J., Stolbrink M., Christian H.C., Wray J., Bishop-Bailey D., Berney D.M., Wass J.A., Popovic V., Ribeiro-Oliveira A., Gadelha M.R., Monson J.P., Akker S.A., Davis J.R., Clayton R.N., Yoshimoto K., Iwata T., Matsuno A., Eguchi K., Musat M., Flanagan D., Peters G., Bolger G.B., Chapple J.P., Frohman L.A., Grossman A.B., Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 2008, 93:2390-2401.
53. Libe R., Fratticci A., Coste J., Tissier F., Horvath A., Ragazzon B., Rene-Corail F., Groussin L., Bertagna X., Raffin-Sanson M.L., Stratakis C.A., Bertherat J. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin. Cancer Res. 2008, 14:4016-4024.
54. Luccio-Camelo D.C., Une K.N., Ferreira R.E., Khoo S.K., Nickolov R., Bronstein M.D., Vaisman M., Teh B.T., Frohman L.A., Mendonca B.B., Gadelha M.R. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur. J. Endocrinol. 2004, 150:643-648.
55. Ma Q., Whitlock J.P. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Biol. Chem. 1997, 272:8878-8884.
56. Marlowe J.L., Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell Biochem. 2005, 96:1174-1184.
57. Marlowe J.L., Knudsen E.S., Schwemberger S., Puga A. The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. J. Biol. Chem. 2004, 279:29013-29022.
58. Marlowe J.L., Fan Y., Chang X., Peng L., Knudsen E.S., Xia Y., Puga A. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol. Biol. Cell 2008, 19:3263-3271.
59. McCarthy M.I., Noonan K., Wass J.A., Monson J.P. Familial acromegaly: studies in three families. Clin. Endocrinol. (Oxf.) 1990, 32:719-728.
60. Meyer B.K., Pray-Grant M.G., Vanden Heuvel J.P., Perdew G.H. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell Biol. 1998, 18:978-988.
61. Montanana, C.F., Daly, A.F., Tichomirowa, M.A., Vanbellinghen, J.F., Theodoropoulou, M., Serrano, C.T., Suarez, P.R., Vela, J.G., Hagelstein, M.T., Bours, V., Beckers, A., 2008. Occurrence of AIP mutations in sporadic pituitary adenomas and familial isolated pituitary adenomas kindreds in Valencia, Spain. In: Proceedings of the 90th Annual Meet of the Endocrine Society, pp. 3-775.
62. Montanana C.F., Daly A.F., Tichomirowa M.A., Vanbellinghen J.F., Jaffrain-Rea M.L., Trescoli Serrano C., Riesgo Suares P., Gomez Vela J., Tenes S., Bours V., Beckers A. TSH-secreting pituitary adenoma in a male patient with a novel missense AIP mutation. Proceedings of the 91st Annual Meeting of the Endocrine Society 2009, pp. 1-668.
63. Nakata A., Urano D., Fujii-Kuriyama Y., Mizuno N., Tago K., Itoh H. G-protein signalling negatively regulates the stability of aryl hydrocarbon receptor. EMBO Rep. 2009, 10:622-628.
64. Naves L.A., Daly A.F., Vanbellinghen J.F., Casulari L.A., Spilioti C., Magalhaes A.V., Azevedo M.F., Giacomini L.A., Nascimento P.P., Nunes R.O., Rosa J.W., Jaffrain-Rea M.L., Bours V., Beckers A. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur. J. Endocrinol. 2007, 157:383-391.
65. Nishimura N., Miyabara Y., Sato M., Yonemoto J., Tohyama C. Immunohistochemical localization of thyroid stimulating hormone induced by a low oral dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats. Toxicology 2002, 171:73-82.
66. Oesch-Bartlomowicz B., Huelster A., Wiss O., Antoniou-Lipfert P., Dietrich C., Arand M., Weiss C., Bockamp E., Oesch F. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc. Natl. Acad. Sci. USA 2005, 102:9218-9223.
67. Paajarvi G., Viluksela M., Pohjanvirta R., Stenius U., Hogberg J. TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents. Carcinogenesis 2005, 26:201-208.
68. Pang P.H., Lin Y.H., Lee Y.H., Hou H.H., Hsu S.P., Juan S.H. Molecular mechanisms of p21 and p27 induction by 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, involved in antiproliferation of human umbilical vascular endothelial cells. J. Cell. Physiol. 2008, 215:161-171.
69. Park J.H., Mangal D., Frey A.J., Harvey R.G., Blair I.A., Penning T.M. Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2'-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7,8-dione. J. Biol. Chem. 2009, 284:29725-29734.
70. Peng L., Mayhew C.N., Schnekenburger M., Knudsen E.S., Puga A. Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors. Toxicology 2008, 246:242-247.
71. Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988, 263:13802-13805.
72. Pesatori A.C., Baccarelli A., Consonni D., Lania A., Beck-Peccoz P., Bertazzi P.A., Spada A. Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur. J. Endocrinol. 2008, 159:699-703.
73. Pestell R.G., Alford F.P., Best J.D. Familial acromegaly. Acta Endocrinol. (Copenh.) 1989, 121:286-289.
74. Petrulis J.R., Kusnadi A., Ramadoss P., Hollingshead B., Perdew G.H. The hsp90 Co-chaperone XAP2 alters importin beta recognition of the bipartite nuclear localization signal of the Ah receptor and represses transcriptional activity. J. Biol. Chem. 2003, 278:2677-2685.
75. Prescott R.W.G., Spruce B.A., Kendall-Taylor P., Hall K., Hall R. Acromegaly and gigantism presenting in two brothers. 1st Joint Mtg. Brit. Endocr. Soc. 1982, p.49.
76. Puga A., Barnes S.J., Dalton T.P., Chang C., Knudsen E.S., Maier M.A. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J. Biol. Chem. 2000, 275:2943-2950.
77. Raitila A., Georgitsi M., Karhu A., Tuppurainen K., Makinen M.J., Birkenkamp-Demtroder K., Salmenkivi K., Orntoft T.F., Arola J., Launonen V., Vahteristo P., Aaltonen L.A. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr. Relat. Cancer 2007, 14:901-906.
78. Ramadoss P., Perdew G.H. The transactivation domain of the Ah receptor is a key determinant of cellular localization and ligand-independent nucleocytoplasmic shuttling properties. Biochemistry 2005, 44:11148-11159.
79. Ray S., Swanson H.I. Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: a tumor promoting event?. Biochem. Pharmacol. 2009, 77:681-688.
80. Reyes H., Reisz-Porszasz S., Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992, 256:1193-1195.
81. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42:260-266.
82. Schrag S.D., Dixon R.L. Occupational exposures associated with male reproductive dysfunction. Annu. Rev. Pharmacol. Toxicol. 1985, 25:567-592.
83. Sewall C.H., Flagler N., Vanden Heuvel J.P., Clark G.C., Tritscher A.M., Maronpot R.M., Lucier G.W. Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1995, 132:237-244.
84. Sikka S.C., Wang R. Endocrine disruptors and estrogenic effects on male reproductive axis. Asian J. Androl. 2008, 10:134-145.
85. Soares B.S., Eguchi K., Frohman L.A. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J. Clin. Endocrinol. Metab. 2005, 90:6580-6587.
86. Sumanasekera W.K., Tien E.S., Turpey R., Vanden Heuvel J.P., Perdew G.H. Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J. Biol. Chem. 2003, 278:4467-4473.
87. Toledo R.A., Lourenco D.M., Liberman B., Cunha-Neto M.B., Cavalcanti M.G., Moyses C.B., Toledo S.P., Dahia P.L. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metab. 2007, 92:1934-1937.
88. Trivellin, G., Occhi, G., Albiger, N., Ceccato, F., Rizzati, S., Ferasin, S., Mantero, F., Scaroni, C., 2010. AHRR is overexpressed in somatotropinomas. In: Proceedings of the XXXIV Giornate Endocrinologiche Pisane, PISA, 10/12 June 2010.
89. Turner J.J., Christie P.T., Pearce S.H., Turnpenny P.D., Thakker R.V. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum. Mutat. 2010, 31:E1089-E1101.
90. Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I., Melcarne A., Rimondini R., Romeo G., Bonora E. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J. Clin. Endocrinol. Metab. 2009, 94:2571-2578.
91. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., Tuppurainen K., Ebeling T.M., Salmela P.I., Paschke R., Gundogdu S., De M.E., Makinen M.J., Launonen V., Karhu A., Aaltonen L.A. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
92. Vogel C.F., Sciullo E., Park S., Liedtke C., Trautwein C., Matsumura F. Dioxin increases C/EBPbeta transcription by activating cAMP/protein kinase A. J. Biol. Chem. 2004, 279:8886-8894.
93. Weiss C., Faust D., Schreck I., Ruff A., Farwerck T., Melenberg A., Schneider S., Oesch-Bartlomowicz B., Zatloukalova J., Vondracek J., Oesch F., Dietrich C. TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene 2008, 27:2198-2207.
94. Yamada S., Yoshimoto K., Sano T., Takada K., Itakura M., Usui M., Teramoto A. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 1997, 82:239-242.
95. Yaneva, M., Daly, A.F., Tichomirowa, M.A., Vanbellinghen, J.F., Hagelstein, M.T., Bours, V., Zacharieva, S., Beckers, A., 2008. Aryl hydrocarbon receptor interacting protein gene mutations in bulgarian FIPA and young sporadic pituitary adenoma patients. In: Proceedings of the 90th Annual Meeting of the Endocrine Society, pp. 3-520.
96. Yano M., Terada K., Mori M. AIP is a mitochondrial import mediator that binds to both import receptor Tom20 and preproteins. J. Cell Biol. 2003, 163:45-56.
97. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzalez N., Martinez A., Narayan G., Kirsch I., Franklin W., Hirsch F., Birrer M., Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J. Clin. Invest. 2008, 118:640-650.